Upper tract urothelial carcinoma (UTUC) is an increasingly common cancer in Australia. There is limited information to how these patients are managed following their index procedure, and whether follow-up is completed in accordance with EAU guidelines. This survey aimed to assess attitudes amongst a small cohort of trainees regarding UTUC management.

A cross-sectional survey was distributed to current urology trainees in Victoria, Australia. It was designed to test adherence to EUA guidelines for the management of UTUC. The survey included demographics, treatment received, length of follow-up, and methods utilized to monitor for recurrence.

The survey was distributed in late 2023, with a total of 10 responses, with more expected. Most respondents were senior trainees. For patients with low-grade UTUC 87.5% of respondents followed patients for 5 years. 50% of respondents performed the first urine cytology test and flexible cystoscopy within 3 months of the index procedure. For patients with high-grade UTUUC only 75% of respondents followed patients life-long. 100% of respondents performed annual urine cytology and flexible cystoscopy.

UTUC is increasingly common with a poor prognosis. Although limited, our data suggests that there is inconsistent adherence to the EAU guidelines in longitudinal monitoring. Further work is needed to determine whether non-compliance increases rates of delayed detection of recurrence, or whether changes in policy need to reflect differences in Australian practice.